Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
AIO-Studien-gGmbH
ClinicalTrials.gov Identifier:
NCT01200121
First received: September 9, 2010
Last updated: October 21, 2013
Last verified: October 2013

September 9, 2010
October 21, 2013
February 2010
October 2013   (final data collection date for primary outcome measure)
paracentesis-free survival (ParFS) [ Time Frame: one year ] [ Designated as safety issue: No ]
The first primary endpoint will consist of paracentesis-free survival (ParFS) which will be calculated as the time period between the initial puncture after randomization to the first subsequent paracentesis or other symptomatic treatments for ascites with the exception of diuretics or until death (whichever occurs first)
Same as current
Complete list of historical versions of study NCT01200121 on ClinicalTrials.gov Archive Site
  • Best Response (BR) [ Time Frame: 12 weeks from 1st application ] [ Designated as safety issue: No ]
    Best Response representing the longest period of time from one paracentesis until next paracentesis within the treatment period or, if longer, from the last paracentesis performed within the treatment period until first subsequent symptomatic treatment for ascites with the exception of diuretics (before end of the standard 4 week follow-up) or, if longer, from the last paracentesis performed within the treatment period until death (before end of the standard 4 week follow-up) or, if longer, from the last paracentesis performed within the treatment period until 4 week follow-up
  • Volume of ascites [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Volume of ascites drained by routine paracentesis (ascites volume minus lavage volumes, if applicable)
  • Quality of life [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Quality of life as assessed by standardized questionnaires
  • Changes in ECOG performance status [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: Yes ]
    Calculation: 12 weeks minus baseline
  • Pharmacokinetics of Bevacizumab and VEGF concentrations [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Proportions of patients with adverse events grades 3, 4, or 5. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Proportions of patients with adverse events of special interest [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
    any grade of gastrointestinal perforation, gastrointestinal fistulas or other internal fistulas, wound-healing disturbances, hemorrhagic events and arterial thrombo-embolic events.
  • All adverse events [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Changes in laboratory values and vital signs. [ Time Frame: baseline, every two weeks up to week 12 ] [ Designated as safety issue: Yes ]
    Calculation: Value from later timepoints minus baseline value
  • Best Response (BR) [ Time Frame: 12 weeks from 1st application ] [ Designated as safety issue: No ]
    Best Response representing the longest period of time from one paracentesis until next paracentesis within the treatment period or, if longer, from the last paracentesis performed within the treatment period until first subsequent symptomatic treatment for ascites with the exception of diuretics (before end of the standard 4 week follow-up) or, if longer, from the last paracentesis performed within the treatment period until death (before end of the standard 4 week follow-up)or, if longer, from the last paracentesis performed within the treatment period until 4 week follow-up
  • Volume of ascites [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Volume of ascites drained by routine paracentesis (ascites volume minus lavage volumes, if applicable)
  • Quality of life [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Quality of life as assessed by standardized questionnaires
  • Changes in ECOG performance status [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics of Bevacizumab and VEGF concentrations [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Proportions of patients with adverse events grades 3, 4, or 5. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Proportions of patients with adverse events of special interest [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
    any grade of gastrointestinal perforation, gastrointestinal fistulas or other internal fistulas, wound-healing disturbances, hemorrhagic events and arterial thrombo-embolic events.
  • All adverse events [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Changes in laboratory values and vital signs. [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers
Double-blind, Placebo-controlled, Randomized Phase II-study Investigating the Efficacy of Bevacizumab for Symptom Control in Patients With Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers

Malignant ascites represents a severe clinical problem for physicians and patients being confronted with this common symptom of advanced-stage gastrointestinal cancer. Unfortunately, there is no standardized and evidence-based treatment for malignant ascites and therapies which are commonly being used are only temporarily effective. Newer modes of therapy, such as the application of the tri-functional antibody catumaxomab, are associated with significant side effects and are limited to patients in stages of good overall performance. Therefore, there is still an urgent need for more effective, longer-lasting, and less toxic modes of treatment for peritoneal effusions caused by gastrointestinal cancers.

Preclinical data strongly suggest that bevacizumab might be a very effective agent for the treatment of malignant ascites, which is in large part caused by the hyperpermeability-promoting factor VEGF. Emerging clinical results from cancer patients with malignant ascites treated with bevacizumab add further support to this idea. Bevacizumab has been tested in a variety of large clinical trials, has a good toxicity profile, and is effective in a number of human cancers underlying malignant ascites.

In the present study, Bevacizumab will be administered as an intraperitoneal infusion at an absolute standardized dosage of 400 mg. This dosage was chosen because it is comparable to the approved standard dosage for intravenous administration which was also used in both studies reporting the successful and safe intraperitoneal administration of Bevacizumab to patients with malignant ascites. Finally, a standardized dosage seems more practical in the particular patient population treated in this study.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
  • Malignant Ascites
  • Gastrointestinal Cancers
  • Drug: Bevacizumab
    Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of 400 mg Bevacizumabafter paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
    Other Name: Avastin
  • Other: Placebo
    Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of Placebo after paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
  • Experimental: Arm A Bevacizumab
    48 patients randomized into arm A will receive repeated intra¬peritoneal application of Bevacizumab
    Intervention: Drug: Bevacizumab
  • Placebo Comparator: Arm B Placebo
    26 patients randomized into arm B will receive repeated intra¬peritoneal application of Placebo
    Intervention: Other: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
53
Not Provided
October 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age >= 18 years
  2. Written informed consent has been obtained prior to inclu¬sion into the study
  3. Patient is capable and willing to comply with the study
  4. Histologically confirmed esophageal, gastric, pancreatic, cholangiocellular, hepatocellular, or colorectal carcinoma
  5. Cytologically confirmed ascites OR diagnosis of an exsudate (total protein in ascites > 30 g/l) clinically suggestive for malignant ascites OR morphological diagnosis of peritoneal carcinosis by CT , MRT or ultrasound
  6. Ascites clinically judged as not responsive to conventional systemic therapies for primary malignancy
  7. Ascites clinically judged as not responsive to diuretics
  8. At the time of inclusion paracentesis required at least twice within past 4 weeks.
  9. Before inclusion of the patient into the study, a 4-week screening period will allow for a stringent evaluation of the patient regarding fulfillment of inclusion and exclusion criteria. Importantly, no treatments for malignant ascites other than paracentesis and diuretics are allowed during the 4-week screening period.
  10. ECOG performance score 0-3
  11. Life expectancy > 12 weeks
  12. Laboratory parameters:

Hematology

  • Neutrophils > 1,500/µl
  • Platelets > 100,000/µl
  • Hemoglobin >= 9 g/dl or 5.59 mmol/l Hemastasiology
  • INR <= 1.5 x ULN and aPTT <= 1.5 x ULN within past 7 dClinical chemistry
  • Creatinine clearance > 30 ml/min, serum creatinine < 2.5 x ULN
  • Serum bilirubin < 3.0 x ULN
  • Alkaline phosphatase and transaminases < 3.0 x ULN (in case of liver metastases < 7 x ULN)

Urinalysis:

  • Patients with < 2+ proteinuria on dipstick urinalysis.
  • Patients with >= 2+ proteinuria on dipstick urinalysis, who demonstrate < 2.0 g of protein/24 h on 24-h urine collection

Exclusion Criteria:

  1. Concomitant malignancies other than gastrointestinal cancers (Patients with curatively treated basal and squamous cell carcino¬ma of the skin and / or in-situ carci¬noma of the cervix are eli¬gible).
  2. Bacterial peritonitis as indicated by laboratory results (neutrophil count > 250 / µl ascites) or clinical suspicion
  3. Hemorrhagic ascites (ascites hematocrit > 2%)
  4. Transudative ascites (total protein in ascites < 30 g/l)
  5. Parallel treatment with anti-tumor agents other than the study medication from inclusion into the study until safety follow-up. Chemotherapy may be continued if started before screening phase (- 4 weeks before inclusion). Parallel Treatment with Bevacizumab i.v. is not allowed.
  6. Therapy naïve patients
  7. Parallel treatment of ascites with measures other than para¬centesis, diuretics, and the study drugs from 4 weeks before inclusion into the study until safety follow-up.
  8. Patients with extensive metastases of the liver making up > 70% of the total liver mass
  9. Child C cirrhosis of the liver
  10. Occlusion or thrombosis of the portal vein.
  11. Evidence of current and symptomatic central nervous system (CNS) metas¬ta¬ses or spinal cord compression.
  12. Clinically significant cardiovascular diseases, e.g., un¬con¬trolled hypertension, uncontrolled arrhythmia, hemoptoe, cardiovascular accident within the last 6 months before treatment start, unstable angina, congestive heart failure (CHF) NYHA grade III/IV, symptomatic coronary heart disease, peripheral arterial disease stage >= II.
  13. History of fistula formation involving an internal organ (e.g. tracheo-oesophagal, bronchopleural, biliary, vagina and bladder)
  14. Major surgical procedure, open biopsy, or significant trau¬matic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study.
  15. Concomitant treatment with intravenous Bevacizumab for primary malignancy from inclusion into study until safety follow-up. Prior treatment with Bevacizumab for primary malignancy is not exclusionary.
  16. Serious non-healing wound, ulcer or bone fracture.
  17. Radiotherapy for purposes other than local control of symp¬toms.
  18. Evidence of bleeding diathesis or coagulopathy.
  19. Hematopoietic diseases.
  20. Known intra-abdominal inflammatory process or serious gastrointestinal ulceration.
  21. History of chronic intestinal diseases associated with severe diarrhea.
  22. Thrombo-embolic events or severe hemorrhage (<= 6 months before treatment start).
  23. Known hypersensitivity to the test drug Bevacizumab
  24. Evidence of any other disease, metabolic dysfunction, physi¬cal examination finding, or laboratory finding giving reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug or puts the patient at high risk for treatment-related compli¬cations.
  25. With the only exception of full dose (INR > 1.5) oral coumarin-derived anticoagulants, the use of full dose anticoagulants is allowed as long as the INR or a PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for at least two weeks at the time of randomisation.
  26. Patients who participated within the last 30 days prior to enrolment in a clinical trial and received a non approved investigational drug (e.g. follow up within the trial is not exclusionary).
  27. Patients who have participated in this study before.
  28. Women, lactating, pregnant or of childbearing potential and fertile men not using a highly effective contraceptive method . [Women of childbearing potential must have a negative pregnancy test (serum ß HCG) within 7 days before the first dose of study drug].
  29. Patients who are committed to an institution by virtue of an order issued either by the judicial or the administra¬tive authorities (according to § 40 (1) 4 AMG).
  30. Patients who are underage or patients who are incapable to understand the aim, importance and consequences of the study and to give legal informed consent (according to § 40 (4) and § 41 (2) and (3) AMG).
  31. Patients with a history of a psychological illness or con¬di¬tion such as to interfere with the patient's ability to un¬der¬stand the requirements of the study.
  32. Patients who possibly are dependent on the sponsor or investigator.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01200121
AIO-SUP-0108
Yes
AIO-Studien-gGmbH
AIO-Studien-gGmbH
Not Provided
Principal Investigator: Karin Jordan, Dr. med. Universitätslinikum der Martin-Luther Universität Halle-Wittenberg
AIO-Studien-gGmbH
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP